Literature DB >> 10438693

Comparative efficacy of sertraline vs. fluoxetine in patients age 70 or over with major depression.

S I Finkel1, E M Richter, C M Clary, E Batzar.   

Abstract

Using data from a larger 12-week clinical trial, the authors evaluated the comparative efficacy and safety of sertraline (n=42) and fluoxetine (n=33) in patients over age 70 with a diagnosis of major depressive disorder. Similar improvement on measures of depression, including remission of depressive symptoms, was evident, although significantly more sertraline-treated patients achieved a criterion clinical response. Significantly greater improvement for the sertraline group was apparent on the Digit Symbol Substitution Test, but not on two other measures of cognitive functioning. Although there was no difference in the rate of adverse events experienced, fluoxetine-treated patients lost significantly more body weight over the 12-week trial than did sertraline-treated patients, whereas the latter group exhibited significantly more "shaking. "

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438693     DOI: 10.1097/00019442-199908000-00006

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  11 in total

1.  Change in cognitive functioning in depressed older adults following treatment with sertraline or nortriptyline.

Authors:  Michelle E Culang-Reinlieb; Joel R Sneed; John G Keilp; Steven P Roose
Journal:  Int J Geriatr Psychiatry       Date:  2011-09-15       Impact factor: 3.485

2.  Acute treatment with the antidepressants bupropion and sertraline do not influence memory retrieval in man.

Authors:  André F Carvalho; Cristiano A Köhler; Eduardo P Cruz; Pablo L Stürmer; Bruno P Reichman; Bianca M Barea; Iván Izquierdo; Márcia L F Chaves
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-05-10       Impact factor: 5.270

Review 3.  A meta-analysis of the effects of antidepressants on cognitive functioning in depressed and non-depressed samples.

Authors:  Catherine E Prado; Stephanie Watt; Simon F Crowe
Journal:  Neuropsychol Rev       Date:  2018-02-14       Impact factor: 7.444

Review 4.  Spotlight on sertraline in the management of major depressive disorder in elderly patients.

Authors:  Richard B R Muijsers; Greg L Plosker; Stuart Noble
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 5.  Selective serotonin reuptake inhibitors for late-life depression: a comparative review.

Authors:  L K Solai; B H Mulsant; B G Pollock
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 6.  Fluoxetine versus other types of pharmacotherapy for depression.

Authors:  A Cipriani; P Brambilla; T Furukawa; J Geddes; M Gregis; M Hotopf; L Malvini; C Barbui
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19

7.  Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease.

Authors:  Cynthia A Munro; Crystal Flynn Longmire; Lea T Drye; Barbara K Martin; Constantine E Frangakis; Curtis L Meinert; Jacobo E Mintzer; Anton P Porsteinsson; Peter V Rabins; Paul B Rosenberg; Lon S Schneider; Daniel Weintraub; Constantine G Lyketsos
Journal:  Am J Geriatr Psychiatry       Date:  2012-12       Impact factor: 4.105

Review 8.  Sertraline: a review of its use in the management of major depressive disorder in elderly patients.

Authors:  Richard B R Muijsers; Greg L Plosker; Stuart Noble
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 9.  Time course of response to antidepressants in late-life major depression: therapeutic implications.

Authors:  Ellen M Whyte; Mary Amanda Dew; Ariel Gildengers; Eric J Lenze; Ashok Bharucha; Benoit H Mulsant; Charles F Reynolds
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 10.  Comparative risk for harms of second-generation antidepressants : a systematic review and meta-analysis.

Authors:  Gerald Gartlehner; Patricia Thieda; Richard A Hansen; Bradley N Gaynes; Angela Deveaugh-Geiss; Erin E Krebs; Kathleen N Lohr
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.